ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
C2 Pharma, a supplier of niche active pharmaceutical ingredients (APIs), has acquired the digoxin API business of the Polish firm Nobilus Ent. C2 says the purchase complements production of digoxin that the Indian firm Laurus Labs conducts on its behalf. Digoxin is a plant extract used to treat heart conditions. C2 says it is responding to supply inconsistency due to high impurity levels and an unreliable supply chain.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X